- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00722215
Endothelin Receptor Antagonism in Proteinuric Nephropathy
The Systemic & Renal Effects of Endothelin Receptor Antagonism in Proteinuric Nephropathy
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Response to ETA Receptor Antagonism/Nifedipine/Placebo Prior to the study visit subjects will be asked to refrain from alcohol for 24 hours. Tea and coffee will not be permitted for at least 12 hours before each visit. Studies will be conducted in a quiet, temperature-controlled room.
On arrival at the Clinical Research Centre on the study day, a brief medical enquiry and examination will confirm the ongoing suitability of the subject for the study. An intravenous cannula will be inserted into the antecubital fossa of each arm. We have developed a basic protocol described fully in our previous studies that allows us to measure systemic haemodynamics by the well validated technique of bioimpedance and renal function by standard para-aminohippurate (PAH; renal blood flow) and inulin (glomerular filtration rate) clearance studies.
Urinary protein excretion will be measured by collecting urine over 30 minute time periods. To ascertain the contribution of renal haemodynamics to any change in protein excretion renal blood flow and glomerular filtration rate will be measured. In addition, blood and urine will also be assayed for sodium, creatinine and osmolality to allow calculation of fractional excretion of sodium and free water clearance.
Systemic haemodynamic monitoring will be performed at 15 minute intervals during drug/placebo administration and at 30 minute intervals outwith these periods.
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Scotland
-
Edinburgh, Scotland, Storbritannia, EH4 2XU
- Clinical Research Centre, Western General Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male or female
- Age 18-70
- Body mass index <35
- Blood pressure <160/110 mmHg
- CKD stage 2-5 as per the K/DOQI classification
- Proteinuria in one of the following categories: 0.3-1.5, >1.5-3.0, and >3.0-6.0 g/24hrs
- Normal serum albumin
Exclusion Criteria:
- Subject is below the age of legal consent, or is mentally or legally incapacitated
- History of multiple and/or severe allergic reactions to drugs (including study drugs), or food
- The subject has donated blood (450 ml) within the last 4 weeks
- Past or present drug or alcohol abuse including intravenous drug abuse at any time
- Participation in another clinical trial within 1 month
- Considered to be at high risk of HIV or hepatitis B
- Pregnant
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: 1
Placebo control arm of study
|
Single 15ml 0.9% saline infused for 15 mins as placebo control
|
|
Eksperimentell: 2
BQ-123 arm of study
|
Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.
|
|
Aktiv komparator: 3
Nifedipine arm of study
|
Single dose of nifedipine 10 mg given orally as active control
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Proteinuria
Tidsramme: Acute change in proteinuria over 4 hour period following BQ-123 dosing
|
Acute change in proteinuria over 4 hour period following BQ-123 dosing
|
|
Blood pressure
Tidsramme: Acute change in blood pressure over 4 hour period following BQ-123 dosing
|
Acute change in blood pressure over 4 hour period following BQ-123 dosing
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Arterial stiffness (as measured by pulse wave velocity)
Tidsramme: Acute change in arterial stiffness over 4 hour period following BQ-123 dosing
|
Acute change in arterial stiffness over 4 hour period following BQ-123 dosing
|
|
Endothelial function (as measured by flow-mediated dilatation)
Tidsramme: Acute change in endothelial function over 4 hour period following BQ-123 dosing
|
Acute change in endothelial function over 4 hour period following BQ-123 dosing
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urologiske sykdommer
- Urologiske manifestasjoner
- Nyreinsuffisiens
- Vannlatingsforstyrrelser
- Nyresykdommer
- Nyresvikt, kronisk
- Proteinuri
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Vasodilaterende midler
- Membrantransportmodulatorer
- Kalsiumregulerende hormoner og midler
- Reproduktive kontrollmidler
- Kalsiumkanalblokkere
- Tokolytiske midler
- Endotelinreseptorantagonister
- Nifedipin
- Endothelin A Receptor Antagonists
Andre studie-ID-numre
- 2006/WCRC/02
- PG/05/91
- 06/MRE00/12
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .